{
  "image_filename": "table_p2_det_1_017.png",
  "image_path": "FlublokPI/extracted/figures/table_p2_det_1_017.png",
  "image_type": "Table",
  "page_number": 2,
  "block_id": "det_1_017",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "Partial table showing percentages (<1, 1, 6, 5, 3, 2, 0) of severe responses reported by subjects across studies, with footnotes defining severity grades (temperature ranges) and referencing Studies 3 and 4 of a U.S.-licensed IIV3 in clinical trials. The content is safety/reactogenicity data, not immunogenicity or cross-protection. does not support the claim because the table presents adverse event rates and severity definitions, not data on immune response breadth or cross-protection in mismatch seasons. Note: Table is limited to safety/reactogenicity; no immunogenicity or cross-protection data are visible.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Partial table showing percentages (<1, 1, 6, 5, 3, 2, 0) of severe responses reported by subjects across studies, with footnotes defining severity grades (temperature ranges) and referencing Studies 3 and 4 of a U.S.-licensed IIV3 in clinical trials. The content is safety/reactogenicity data, not immunogenicity or cross-protection.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table presents adverse event rates and severity definitions, not data on immune response breadth or cross-protection in mismatch seasons.",
    "confidence_notes": "Table is limited to safety/reactogenicity; no immunogenicity or cross-protection data are visible."
  }
}